Rubius Therapeutics Highlights Preclinical Oncology Data at Society for Immunotherapy of Cancer Annual Meeting and AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    NEXT STORY
     Replimune Presents Initial Clinical Data with RP1 that Strongly Supports Expansion of Clinical Programs in Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC)
    PREV STORY
    Hua Medicine to Release Phase III 24-Weeks Topline Data of Dorzagliatin Monotherapy Trial (HMM0301) on November 12
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma

    The three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, ...

    author_avatar
    NASDAQ Market News

    ITL Pharma Receives United States Patent Protection for Carcinin® Using Halogenated Phenol Ethers for Diagnostics, Antioxidant Protection and Drug Delivery

    KINGSPORT, Tenn., Nov. 26, 2018 (GLOBE NEWSWIRE) -- ITL Pharma, Inc. (ITL), a LIAS ...

    author_avatar
    NASDAQ Market News

    RedHill Biopharma Late-Breaking Abstract on Positive Phase III Crohn’s Disease Study with RHB-104 to be Presented at UEG Week 2018

    TEL-AVIV, Israel and RALEIGH, N.C., Oct. 10, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. ...

    author_avatar
    NASDAQ Market News